A Decision Score provides prognostic discrimination for 10-year locoregional recurrence, with rising score associated with ...
Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...
SAN ANTONIO – Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ...
Please provide your email address to receive an email when new articles are posted on . Results showed a lower 2-year cumulative rate of invasive ipsilateral breast cancer among patients assigned ...
Impact of HER2 low status on pathologic response after neoadjuvant chemotherapy in TNBC: A large scale retrospective cohort study. Impact of postmastectomy radiotherapy on health-related quality of ...
SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer versus guideline-recommended treatment, the randomized COMET ...
December 10, 2010 (San Antonio, Texas) — "Nobody knows whether patients with HER2-positive ductal carcinoma in situ (DCIS) have increased local recurrence of disease," said Lia Halasz, MD, a radiation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results